Herein, we proposed that FXR agonists may contribute to switching from TNFR1-mediated cancer cell survival signaling to pro-apoptotic states, and combined treatments with FXR agonists and pro-apoptotic drugs may produce more potent anti-tumor effects in HCC. The gene discussed is NR1H4; the disease is cancer.